A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule
Olfa Derbel(Hôpital Edouard Herriot), Xavier Thomas(Hôpital Lyon Sud), Giovanna Cannas(Hôpital Edouard Herriot), Fiorenza Barraco(Hôpital Lyon Sud), Youcef Chelghoum(Hôpital Edouard Herriot), Jacques Troncy(Hôpital Edouard Herriot), Mauricette Michallet(Université Claude Bernard Lyon 1), Franck Nicolini(Hôpital Edouard Herriot), Emmanuelle Nicolas‐Virelizier(Hôpital Edouard Herriot), Quoc‐Hung Le(Hôpital Edouard Herriot), Mohamed Elhamri(Hôpital Edouard Herriot)
Cited by 2
Related Papers
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
|The Lancet|2012|1k
Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials
|Journal of Clinical Oncology|2003|606
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
|Journal of Clinical Oncology|2009|562
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
|Journal of Clinical Oncology|2004|547